Phenolaeis will research, develop and commercialize high performance health and wellness products from natural sources which are sustainably sourced and of the highest quality.


Phenolaeis plans to create an internationally recognized Health and Wellness Company known for its commitment to high quality products supported by scientific and clinical data, outstanding customer service and unrivaled educational programs. Our products are intended to protect against age related degenerative conditions and improve the quality of life for individuals worldwide .


Phenolaeis was established in 2011 and was granted a worldwide license by the Malaysian Palm Oil Board (MPOB) to a portfolio of patents related to the isolation, formulation and methods of use of a water-soluble material produced from the fruit of the oil palm tree. The water-soluble Palm Fruit Bioactives Complex™ (PFBc) produced from the fruit of the oil palm tree has been subjected to extensive scientific study over the past 15 years. The fundamental technology development was led by MPOB which worked in collaboration with scientists from world-renowned universities and institutions such as MIT (Cambridge, MA), Brigham and Women’s Hospital (Boston, MA), Brandeis University (Boston, MA), Wayne State University (Detroit, MI), and CSIRO in Australia. In December 2017, Phenolaeis completed a Joint Venture Partnership with Entorno Agroforestal and Evergreen Health to form Phenolaeis Mexico S.A.P.I. de C.V. Phenolaeis’ operational management is headquartered in Cambridge, MA USA.


Kevin L. Ohashi, PhD, MBA

Chief Executive Officer

Dr. Ohashi has over 15 years of experience developing and leading Life Science technology teams and companies.  Kevin co-founded and was Managing Director of Bay Innovation Group (BIG). BIG founded venture backed companies Cayenne Medical, Inc. (Sports Medicine) and nContact, Inc. (Atrial Fibrillation). He is a founder and Managing Partner at Pond Capital and was a Senior Associate at The Vertical Group. He serves on the Board of Directors for Direct Dermatology, Inc. (Dermatology), DRP Medical, Inc. (Acute Kidney Injury), Tauten, Inc. (Sport Fishing) and MicroVascular Tissues (Regenerative Medicine).

Joseph De Angelo

Head of Research & Clinical Programs

Mr. De Angelo has 27 years of experience developing and leading Life Science technology teams and companies.  Mr. De Angelo is the founder and Principal at Scizyg, performing consulting and contract product development in biotechnology and biopharmaceuticals.  He was Chief Development Officer for Curacyte AG/Apex Bioscience, Inc.  Mr. De Angelo founded and held positions as Chief Scientific Officer and VP of Research for Apex Biosciences as well as serving on the Board of Directors. He managed the development and construction of plant facilities and development programs involving fermentation and downstream processing

What Food Companies Are Saying

“This new natural plant complex, Palm Fruit Bioactives, will allow me to introduce new products or improve on my existing products. The ability to create a highly innovative and unique formulation will allow me to meet my customer’s need for new products with proven science and a secure source of supply”.

Subscribe to our Newsletter